Mycobacterial Diseases

Mycobacterial Diseases
Open Access

ISSN: 2161-1068

+44 1478 350008

Mycobacterial Diseases : Citations & Metrics Report

Articles published in Mycobacterial Diseases have been cited by esteemed scholars and scientists all around the world.

Following are the list of articles that have cited the articles published in Mycobacterial Diseases.

Important citations (315)

giovagnoli s, schoubben a, ricci m (2016) the long and winding road to inhaled tb therapy: not only the bug’s fault. drug development and industrial pharmacy 15: 1-37.

parumasivam t, chang ry, abdelghany s, ye tt, britton wj, et al. (2016) dry powder inhalable formulations for anti-tubercular therapy. advanced drug delivery reviews. 102: 83-101.

yacoob fl, philomina jose b, karunakaran lelitha sd, sreenivasan s (2016) primary multidrug resistant tuberculosis and utility of line probe assay for its detection in smear-positive sputum samples in a tertiary care hospital in south india. journal of pathogens 23.

venturini e, remaschi g, berti e, montagnani c, galli l, et al. (2015)  (2015) what steps do we need to take to improve diagnosis of tuberculosis in children?. expert review of anti-infective therapy.13: 907-22.

gupta a, pandya sm, mohammad i, agrawal ak, mohan m, et al. (2013) particulate pulmonary delivery systems containing anti-tuberculosis agents. critical reviews™ in therapeutic drug carrier systems.

ozeki t, tagami t (2014) drug/polymer nanoparticles prepared using unique spray nozzles and recent progress of inhaled formulation. asian journal of pharmaceutical sciences 9: 236-43.

remy wl. the association between latent tuberculosis infection and diabetes mellitus control in the united states.

Boyilla n, madas s (2016) relationship between diabetes mellitus and pulmonary tuberculosis and the outcome of treatment. international journal of advances in medicine 3:504-508.

chan jg, wong j, zhou qt, leung ss, chan hk (2014) advances in device and formulation technologies for pulmonary drug delivery. aaps pharmscitech 15: 882-97.

ahmed m, omer i, osman sm, ahmed-abakur eh (2017) association between pulmonary tuberculosis and type 2 diabetes in sudanese patients. the international journal of mycobacteriology 6:97.

iqbal n, irfan m, zubairi ab, jabeen k, awan s, et al. (2016)  clinical manifestations and outcomes of pulmonary aspergillosis: experience from pakistan. bmj open respiratory research 3: e000155.

laube bl (2014) the expanding role of aerosols in systemic drug delivery, gene therapy and vaccination: an update. translational respiratory medicine 2: 3.

workneh mh, bjune ga, yimer sa (2016) prevalence and associated factors of diabetes mellitus among tuberculosis patients in south-eastern amhara region, ethiopia: a cross sectional study. plos one 11: e0147621.

gopal p, yee m, sarathy j, low jl, sarathy jp, et al. (2016) pyrazinamide resistance is caused by two distinct mechanisms: prevention of coenzyme a depletion and loss of virulence factor synthesis. acs infectious diseases 2: 616-626.

Garg t, rath g, r murthy r, d gupta u, g vatsala p, et al. (2015) current nanotechnological approaches for an effective delivery of bioactive drug molecules to overcome drug resistance tuberculosis. current pharmaceutical design 21: 3076-3089.

lanoix jp, ioerger t, ormond a, kaya f, sacchettini j, et al. (2016) selective inactivity of pyrazinamide against tuberculosis in c3heb/fej mice is best explained by neutral ph of caseum. antimicrobial agents and chemotherapy 60: 735-43.

ανδρεάδου μ (2015) χρήση νανοσυστημάτων στην ανίχνευση μελÏŽν του γένους leishmania.

sriram r, bhojwani km (2017) manifestations of tuberculosis in otorhinolaryngology practice: a retrospective study conducted in a coastal city of south india. indian journal of otolaryngology and head & neck surgery 1-6.

choudhury s, guha r, verma ak, banerjee sn (2014) tuberculous infection in neck-still a health problem.

choudhury s, guha r, verma ak, banerjee sn. tuberculous infection in neck-still a health problem. skin 3: 87-5.

Top